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Abstract
Antimicrobial resistance to the extended-spectrum cephalosporins is increasingly reported worldwide. 
In the local setting, nosocomial infections with multi-resistant Gram-negative bacilli are not 
uncommon and are a growing concern. However, there is limited data on the carriage rates of such 
organisms in the local setting.  In May 2001, a prospective study was carried out to determine the 
enteric carriage rates of ceftazidime-resistant Gram negative bacilli (CAZ-R GNB) among residents 
of nursing homes and from in-patients of the geriatric and adult haematology wards of University 
Malaya Medical Centre. Ceftazidime-resistant Gram-negative bacilli (CAZ-R GNB) were detected 
in 25 samples (30%), out of which 6 were from nursing home residents, 5 from geriatric in-patients 
and 14 from the haematology unit. A total of 28 CAZ-R GNB were isolated and Escherichia coli 
(10) and Klebsiella pneumoniae (7) were the predominant organisms. Resistance to ceftazidime in 
E. coli and Klebsiella was mediated by extended-spectrum beta-lactamases (ESBLs). Although the 
majority of the CAZ-R GNB were from patients in the haematology ward, the six nursing home 
residents with CAZ-R GNB were enteric carriers of ESBL-producing coliforms. Prior exposure to 
antibiotics was associated with carriage of ESBL organisms and to a lesser extent, the presence of 
urinary catheters.
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INTRODUCTION
Antibiotic resistance among Gram-negative 
bacilli (GNB) is a rapidly expanding problem due 
to the organisms’ ability to mutate, and to acquire 
and transmit plasmids and other mobile genetic 
elements encoding resistance genes1. In the early 
1960’s, ampicillin, carbenicillin, and the narrow-
spectrum cephalosporins were frequently used to 
treat GNB infections. However, plasmid-mediated 
β-lactamase mediated resistance has caused these 
antibiotics to lose their efficacy. In response, 
more stable β-lactams were developed in the late 
1970s and 1980s, notably the expanded spectrum 
β-lactams (penicillins and cephalosporins) 
(ESBs). The extensive use of ESBs over time has 
also led to the selection of the resistant GNB, 
those capable of producing extended-spectrum 
β-lactamases. Extended-spectrum β-lactamases 
or ESBLs are most prevalent in Escherichia 
coli and Klebsiella pneumoniae, but have been 
described in many other Enterobacteriaceae and 
in a few Pseudomonas aeruginosa isolates2,3.
 The selective pressures exerted by the 
expanded use of antimicrobial agents has 
enhanced the development and spread of resistant 
bacteria, not only in hospital settings but in areas 
outside the hospital including nursing homes4,5. 
The growing number of geriatric patients 
harbouring ESBL-producing organisms indicate 
that besides hospitals, long-term care facilities 
and nursing homes are important reservoirs for 
these organisms. Geriatric patients, most of who 
are in an immunocompromised and debilitated 
state, are ideal targets for the infection and 
colonisation of multiply resistant organisms5. 
In Chicago, an outbreak of ceftazidime-resistant 
(CAZ-R) strains of K. pneumoniae and E. coli was 
associated with elderly, nursing home patients6,7. 
An outbreak of ESBL-producing K. pneumoniae 
was also reported in a geriatric hospital in France8. 
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Other factors for development of resistance 
include patient’s prior antibiotic use and number 
of antibiotics used9,10.
 Nosocomial infections with Gram-negative 
bacilli are not uncommon in the local setting 
and can be perceived as a growing threat to 
public health. However, there is limited data 
on the carriage rates of such organisms in the 
local setting. Thus, this prospective study was 
undertaken to evaluate the prevalence of ESBL-
producers among a geriatric population and 
adult haematology in-patients. Evaluation of 
potential risk factors for the enteric carriage of 
ESBL producers was carried out to determine 
possible steps that could be taken to eliminate, 
or at least control, this problem.
MATERIALS AND METHODS 
Sample collection, screening and phenotypic 
confirmation of ESBL production
Over a 3-week period in May and June 2001, 
stool samples were collected from a geriatric 
population consisting of in-patients from the 
Geriatric unit in University Malaya Medical 
Centre (UMMC), and from randomly selected 
nursing homes for the elderly around Petaling 
Jaya, Selangor, as well as from in-patients in the 
adult hematology ward in UMMC. The study 
protocol was approved by the Ethics Committee 
of UMMC prior to any sample collection 
from patients. Data collected included patient 
demographics, prior antibiotic treatment, usage 
of urinary catheter, stay in nursing homes/wards 
and duration of stay/hospitalization.  Stool 
samples were collected from 80 subjects who 
consented to participate in the study and were 
screened for the presence of CAZ-R Gram-
negative bacilli (GNB) using MacConkey agar 
(OXOID, UK) containing 4 µg of ceftazidime. 
Resistance to ceftazidime was used as a marker 
of ESBL production.  All samples were stored at 
room temperature and were centrally processed 
within 2 hours of collection. The CAZ-R 
isolates were subcultured and identified using 
the standard biochemical tests11. Disc diffusion 
susceptibility testing as described by the NCCLS 
was used to determine the antibiograms of the 
isolates whereas the phenotypic confirmation of 
the production of ESBLs was determined using 
the double-disc synergy test (DDST) as described 
previously12,13.
Antimicrobial  suscept ib i l i ty  by  MIC 
determination
The minimum inhibitory concentration of various 
antibiotics was determined using the standard 
agar dilution technique, in accordance with the 
National Committee for Clinical Laboratory 
Standards Guidelines12. All the antibiotics which 
included ceftazidime, cephalexin, cefoperazone, 
cefotaxime and ceftriaxone, were obtained from 
Sigma (USA) with the exception of aztreonam 
(Bristol-Myers-Squibb, Italy), clavulanic acid 
(Smith-Kline and Beecham Ltd., UK) and 
imipenem (Merck and Co. Inc., USA). MIC 
values were also determined for the ß-lactam 
and ß-lactamase inhibitor combination of 
ceftazidime-clavulanic acid. 
Isoelectric focusing
Analytical isoelectric focusing was carried 
out as previously described13 on ampholine 
polyacrylamide gels with broad pH range 
(3-9) (Pharmacia Biotech, Sweeden) using a 
PhastSystem (Pharmacia Biotech, Sweeden). 
Visualization of the ß-lactamases were done 
by staining with nitrocefin, a chromogenic 
cephalosporin (OXOID, UK).
PCR amplification and PCR-SSCP (PCR-single 
stranded conformational polymorphism)
DNA template preparation and subsequent PCR 
amplification of the SHV gene was carried out 
based on the method of M’Zali et al. (1997)14. A 
pair of primers 5’-TCAGCGAAAAACACCTTG-
3’ and 5’-TCCCGCAGATAAATCACCA-3’ 
were used to amplify the 475-bp sequence 
of the blaSHV gene15. The 971-bp fragment of the TEM gene was amplified using 
primers 5’-TCGGGGAAATGTGCG-3’ and 
5 ’ -TGCTTAATCAGTGAGGCACC-3’ , 
while the 396-bp fragment of the AmpC 
gene was amplified using primers 5’-
ATTCGTATGCTGGATCTCGCCACC-3’ and 
5’-CATGACCCAGTTCGCCATATCCTG-3’. 
All primers were synthesized by Genemed 
Biotechnologies Inc., USA.  
 PCR-SSCP was carried out using the method 
of M’Zali et al. (1997)14. Briefly, the 475-bp SHV 
amplicons were digested with PstI, denatured 
with a formamide dye, prior to heating at 950C for 
5 mins. The denatured products were separated 




During the study period, 80 samples were 
collected with 35% (28 samples) being from 
nursing homes and the rest from the wards; 30% 
(24 samples) from the geriatric ward and 35% 
(28 samples) from the adult haematology ward. 
Ceftazidime-resistant gram-negative bacilli 
(CAZ-R GNB) were isolated from 26 samples 
out of which a majority were isolated from the 
haematology ward (51.7%). Five samples from 
the geriatric ward also contained ceftazidime-
resistant (CAZ-R) GNB. Eight samples from five 
of the nursing homes contained CAZ-R GNB 
with one sample having two different CAZ-R 
GNB. Overall, 29 CAZ-R GNB were isolated 
from the 26 samples.
 Escherichia coli was the most commonly 
isolated CAZ-R GNB (34.5% of all CAZ-
R isolates).  Klebsiella spp. was the second 
most frequently isolated (24.1%) followed by 
Enterobacter spp., Proteus spp. and Citrobacter 
spp (10.3%) and P. aeruginosa (6.9%), while 
Acinetobacter spp. was the least commonly 
isolated organism (3.5%).
 From the 29 CAZ-R GNB, 17 extended-
spectrum β-lactamase (ESBL)-producing 
organisms were detected through the double-disc 
synergy test. The 17 organisms consisted of 
10 E. coli and 7 K. pneumoniae, which meant 
that all the isolated E. coli and K. pneumoniae 
were ESBL producers.  Of the 15 CAZ-R GNB 
isolated from haematology ward 53.3% were 
ESBL-producers while 40% of those from the 
geriatric ward were ESBL-producers. 77.8% of 
CAZ-R GNB from nursing homes were ESBL-
producers.
 In this study, association of putative risk 
factors such as prior antibiotic treatment, usage 
of catheter, staying in nursing homes/wards and 
duration of stay with development of ceftazidime 
resistance and ESBL-production in GNB were 
determined using Pearson’s Chi-square test. 
84% of the ESBL-producing GNB came from 
patients with prior antibiotic treatment (p=0.05). 
However, there was not much difference in those 
patients who acquired resistant GNB (10.5%) 
with those who had sensitive isolates in terms 
of catheter usage (8.3%). 
 To determine the effect of duration of stay, 
three patients with initially susceptible isolates 
were followed-up within a week and results show 
that they did not acquire resistant organisms. 
 Further analyses was carried out on the ESBL-
producing E. coli and K. pneumoniae isolates. 
All isolates displayed high level resistance to 
ceftazidime (128 µg/ml), but were susceptible 
to the carbapenem and imipenem. Two of the 
E. coli isolates were resistant to the cephamycin 
and cefoxitin. PCR analyses using AmpC specific 
primers confirmed the presence of the AmpC 
gene. 
 IEF results are summarized in Table 3. Most 
of the isolates were found to produce more than 
one β-lactamase with pI values ranging from 
5.1 to > 9.0, out of which all of these isolates 
produced a β-lactamase with a pI value of 8.2, 
which is the similar pI value of the SHV-5 β-
lactamase. Most of the isolates also produced a 
β-lactamase with the pI value of between 5.1 to 
6.0 which are characteristic of TEM enzymes. 
Two of the isolates produced a β-lactamase with 
the pI value of >9.0 which was indicative of the 
AmpC type β-lactamase.
 The identity of the β-lactamases were further 
confirmed via amplification of the genes using 
primers specific to the blaSHV and blaTEM. The results from the PCR correlated with the data 
obtained from the IEF assay (Table 2).
 PCR-SSCP analysis of the SHV gene was 
carried out on the 17 isolates which had the pI 
value of 8.2. Amplification of the SHV gene 
was consistently obtained from all 17 isolates, 
confirming the presence of the SHV gene. The 
isolates were further analysed using PCR-SSCP. 
13 of the isolates gave an identical pattern to 
that of SHV-5 (Figure 1), while 4 isolates had 
almost identical patterns to that of the SHV-5 
with the exception of an additional band. This 
band did not correspond to any of the other SHV 
controls (SHV-1 to –5).  
DISCUSSION
A majority of the extended-spectrum β-
lactamases belong to the TEM or SHV family 
of β-lactamase genes and are generally located 
on plasmids. These enzymes differ in only 
a few amino acids which, however, result in 
alterations that vary the spectrum of activity 
of these enzymes. ESBL-producing isolates 
are generally resistant to extended-spectrum 
cephalosporins and aztreonam16 as well as to 
many older β-lactam antibiotics.  This has caused 
a major shift from more easily eradicated GNB 
towards more resistant phenotypes, with fewer 
options for treatment. 
 In this study, ceftazidime was selected as the 
representative third-generation cephalosporin 
for the detection of resistant GNB that are 
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NB. Ec – Escherichia coli; Kp – Klebsiella pneumoniae; Isolates were isolated from the following :
i. UMMC wards  : 6D – haematology ward; 13U - geriatric ward.
ii. Nursing homes : NH1 – NH4. 
TABLE 1.  Distribution of ceftazidime-resistant gram negative bacilli (GNB) according to source.
  Sources  Samples containing ceftazidime- % Samples with
  (no. of samples) resistant GNB (no. of isolates) resistant GNB 
 Haematology ward (28) 13 (15) 46.4 
 Geriatric ward (24) 5 (5) 20.8 
 Nursing homes (28) 8 (9) 28.6 
 Total (80)  26 (29) 32.5
TABLE 2. Summary of results of IEF, PCR and PCR-SSCP of ceftazidime-resistant 
  K. pneumoniae and E. coli isolated from geriatric populations in UMMC and 
nursing homes.
 Strain IEF Detection of resistance genes via PCR PCR-
   TEM SHV AmpC SSCP 
 Ec A (NH1) 6.5, 8.2 + + - SHV-5
 Ec F (NH2) 6.5, 8.2 + + - SHV-5
 Ec J (6D) 6.8, 8.2 + + - SHV-5
 Kp N (13U)  8.2, 9.0 - + + SHV-5
 Ec O (6D) 8.2 - + - SHV-5
 Ec 15 (NH3) 6.5, 8.2, 9.0 + + + SHV-5 
 Ec19-1 (NH4) 5.1, 8.2 + + - SHV-5 
 Kp 19-2 (NH4) 6.0, 8.2 - + - - 
 Ec 20 (NH4) 6.0, 8.2 + + - SHV-5
 Ec 21 (NH4) 8.2 - + - SHV-5
 Ec 51b (6D) 8.2 - + - SHV-5
 Kp 53a (6D) 8.2 - + - -
 Ec 57b (13U) 5.4, 8.2 + + - SHV-5
 Kp 63 (6D) 6.5, 8.2 + + - SHV-5
 Kp 64 (6D) 5.4, 8.2 + + - -
 Kp K2a (6D) 6.5, 8.2 + + - -
 Kp L1a (6D) 5.4, 8.2 + + - SHV-5
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possible ESBL producers.  Ceftazidime was used 
because it has a lower rate of being hydrolysed 
as compared to other broad-spectrum β-lactams. 
Therefore it can be concluded that if the GNB 
are capable of hydrolysing ceftazidime, they are 
most likely able to hydrolyse other β-lactams. 
This is due to the mutations that have increased 
the spectrum of ESBL, but also tend to lower 
their efficacy as enzymes. This, in turn, often 
results in enhanced but low-level resistance to 
β-lactams.    
 Studies have shown that among the risk 
factors for acquiring ESBL-producing GNB 
were, staying in nursing homes/wards, longer 
hospital stay, prior use of antibiotics and 
presence of catheters17.  The population studied 
consisted of a geriatric population (including 
those from nursing homes) and haematology 
patients because previous studies indicated that 
these populations are the most likely targets and 
possible reservoirs of ESBL-producing GNB and 
VRE. This could be due to the fact that most 
of these patients are immunocompromised and 
debilitated and have often used multiple drugs 
and invasive devices. 
 Pearson’s chi-square test was carried out 
to determine the risk factors for emergence of 
ESBL-producing GNB.  84.2% of the ESBL-
producing GNB was detected in patients who had 
taken antibiotic beforehand (p=0.05).  Emergence 
of these ESBL-producing GNB might be due to 
selection of these organisms.
 In this study, 58.6% of the CAZ-R GNB 
isolated were ESBL-producers.  This percentage 
is alarmingly high and shows that nursing homes/
wards may be reservoirs for CAZ-R GNB.  Usage 
of urinary catheter was not identified as a major 
risk factor here with only 9% of patients with 
resistant GNB having used a catheter. However, 
this contradicting result might be due to the small 
sample number studied. In addition, the data also 
showed that there was no apparent association 
between the duration of hospitalization and the 
acquisition of resistant organisms. However, the 
small number of patients observed had a short 
stay (1 week), therefore no definite correlation 
could be made. Thus, catheter usage and duration 
of stay cannot be ruled out as possible risk factors 
for the acquisition of resistant organisms.
FIG. 1: PCR-SSCP of amplified SHV gene products from SHV controls and SHV genes isolated from ESBL-
producing E. coli. (Lane 1– SHV-1 control; Lane 2 – SHV-2 control; Lane 3 – SHV-4 control; Lane 4 
– SHV-5 control; Lanes 5 - 10 – isolates)
1         2        3         4         5         6          7          8         9 
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 The preceding studies suggested that various 
antibiotics (gentamicin, imipenem) can be used 
to treat patients with serious infections due to 
CAZ-R GNB but third generation cephalosporins 
should not be used. Only 41.9% of the resistant 
GNB were sensitive to ciprofloxacin and thus 
it should not be used as an empirical treatment 
when a ceftazidime-resistant organism is 
suspected. This is compounded by reports of 
association of ciprofloxacin use and CAZ-R 
which could be a result of plasmid lingkage of 
these resistance determinants11.
 Further analyses of the ESBL-producing 
isolates all of which were E. coli and K. 
pneumoniae, revealed high resistance to 
ceftazidime, cephalexin, and cefoperazone, 
as well as aztreonam,  intermediary to high 
level resistance to cefotaxime, ceftriaxone, and 
susceptibility to the carbapenem, imipenem. This 
is indicative of a characteristic ESBL-producer18. 
All the isolates produced a β-lactamase with the 
pI value of 8.2, indicative of the SHV-5 gene, 
which is the prevalent in UMMC, as indicated 
in previous studies19. PCR-SSCP confirmed the 
presence of the SHV-5 gene. Two of the E. coli 
isolates displayed resistance to cefoxitin and the 
β-lactamase-inhibitor, clavulanate, indicative 
of an AmpC hyperproducer18. Further analyses 
revealed the presence of the AmpC gene, 
which together with the ESBL activity of these 
two isolates suggests the presence of a dual 
mechanism of resistance.
 In conclusion, prior antibiotic exposure 
may predispose to carriage of ESBL-producing 
GNB. Therefore third-generation cephalosporins 
should not be used as empirical treatment in 
patients with possible serious GNB infection 
and have had recent exposure to broad-spectrum 
antibiotics. Organisms with new mutations or 
genes would not survive if there was no selective 
pressure to encourage the emergence of these 
new variants. 
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